SPOTLIGHT -
Slideshow
Author(s):
Once thought untreatable, we now have two FDA-approved medications for TD and a handful of off-label options. More in this research update.
Deutetrabenazine Shows Long Term Efficacy and Safety in Patients with Tardive Dyskinesia
Not All That Writhes Is Tardive Dyskinesia
Austedo XR Approved: A New Treatment Option for Tardive Dyskinesia and Huntington Disease
Managing Tardive Dyskinesia: New Data from Phase 3 Study of Ingrezza
The 2024 APA Annual Meeting: Monday, May 6
Neurocrine Biosciences Announces Collaboration With Participants of Tardive Dyskinesia Awareness Week